LRMR - NASDAQ

Larimar Therapeutics, Inc.

LRMR·NASDAQ

$3.20

-3.0%

HealthcareBiotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$273.97M

EPS-2.2700

P/E Ratio-1.41

Earnings Date08/06/2026

lrmr

Net Common Stock Issuance

Last Annual Value

65.09M

3-Year CAGR

-5%

5-Year CAGR

-3%

10-Year CAGR

-7%

Adjust for Inflation

Larimar Therapeutics, Inc. Competitors Analysis of Net Common Stock Issuance

LRMR · NASDAQ

Company	Net Common Stock Issuance	CAGR 3Y	CAGR 5Y	CAGR 10Y
Larimar Therapeutics, Inc. NASDAQ:LRMR	65.09M	1194.6%	26.8%	76.6%
Alector, Inc. NASDAQ:ALEC	20.00M	98.7%	N/A	N/A
Editas Medicine, Inc. NASDAQ:EDIT	43.34M	-28.2%	-29.5%	-7.8%
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX	302.56M	N/A	N/A	N/A
Lyell Immunopharma, Inc. NASDAQ:LYEL	50.41M	184.0%	-33.6%	N/A
Tenaya Therapeutics, Inc. NASDAQ:TNYA	108.41M	203.8%	-10.5%	N/A
Voyager Therapeutics, Inc. NASDAQ:VYGR	816.00K	-71.1%	5.9%	N/A
Replimune Group, Inc. NASDAQ:REPL	155.73M	-6.0%	-11.5%	N/A
Kyverna Therapeutics, Inc. NASDAQ:KYTX	117.42M	N/A	N/A	N/A
Korro Bio, Inc. NASDAQ:KRRO	685.00K	-82.0%	N/A	N/A
Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO	217.33M	29.4%	N/A	N/A

Larimar Therapeutics, Inc. Fair Value Envelope

LRMR · NASDAQ

Our analysis suggests that LRMR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.2014, this represents a potential HIDDEN relative to our calculated worth for Larimar Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $3.2014

Related Guides

Blog Categories

Continue your LRMR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.